Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals
Decision in the Arzerra Patent Infringement Case
-- Genentech and Biogen Idec have filed for re-hearing in the United States
Copenhagen, Denmark; May 17, 2013 – Genmab A/S (OMX: GEN) announced today that
Genentech and Biogen Idec have filed for a re-hearing en banc (i.e. before all
judges of the court) in the appeal case, where the U.S. Court of Appeals for
the Federal Circuit recently upheld the U.S. District Court's judgment in favor
of GlaxoSmithKline (GSK). The appeal case relates to a patent infringement case
involving Arzerra® brought against GSK by Genentech and Biogen Idec.
Genentech and Biogen Idec claim that the decision from the US court of appeals
announced on April 16, 2013 in favor of GSK was against court precedent and
request the US court of appeals to reconsider the case. The court of appeals
will now decide whether...